Lorpucitinib

Lorpucitinib (JNJ-64251330) is an orally active pan-JAK inhibitor with good enteric selectivity and safety. Lorpucitinib can inhibit the JAK/STAT pathway and reduce the levels of inflammatory biomarkers in serum. Lorpucitinib can be used in the research of familial adenomatous polyposis and gastrointestinal inflammatory diseases[1][2].

Product Specifications

CAS Number

[2230282-02-5]

Product Name Alternative

JNJ-64251330

UNSPSC

12352005

Target

JAK; STAT

Type

Reference compound

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/lorpucitinib.html

Purity

99.95

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NCC(C)(O)C)CC1=NC2=CN=C(NC=C3)C3=C2N1[C@H]4CC[C@H](CC#N)CC4

Molecular Formula

C22H28N6O2

Molecular Weight

408.50

References & Citations

[1]Hüneburg R, et al. Lorpucitinib (JNJ-64251330) in patients with familial adenomatous polyposis (FAP) : Results from a phase 1b study. 2023.|[2]Ma X, et al. A Phase I, Randomized, Multi‐Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants. Clinical Pharmacology & Therapeutics, 2024, 115 (5) : 1075-1084.